SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Koeller, J.
Right arrow Articles by VonHoff, D. D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Koeller, J.
Right arrow Articles by VonHoff, D. D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A phase I trial of recombinant gamma interferon administered intravenously on a daily x 5 schedule

Jim Koeller

University of Texas Health Science Center at San Antonio, Texas 78284

Thomas D. Brown

Brook Army Medical Center, Ft. Sam Houston, Texas 78234

Kenneth Beougher

Brook Army Medical Center, Ft. Sam Houston, Texas 78234

James Golando

Schering Corporation, Kenilworth, NJ 07033

Eric M. Bonnem

Schering Corporation, Kenilworth, NJ 07033

Daniel D. VonHoff

University of Texas Health Science Center at San Antonio, Texas 78284

Objective: To determine the maximally tolerated dose and associated toxicity of r-{gamma}-IFN. In addition, to evaluate the development of serum IFN neutralizing factors. Design: This is an open-labeled, Phase I dose escalating trial.

Setting: This trial was carried out at a Veteran's Administration and Army hospital.

Patients: Patients with advanced malignancies for whom no known effective therapy is available were eligible. Patients must have adequate organ function, a performance status of 2 or lower and a minimal life expectancy of 2 months.

Intervention: Patients received escalating doses of r-{gamma}-IFN (0.5, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 X 106 IU/m2) daily for 5 days given intravenously over 2 hours every other week.

Main Outcome Measures: Tumor response was followed clinically, with radiographic support when appropriate. Toxicity was evaluated using the World Health Organization (WHO) standard toxicity grading guidelines. Serum samples were used to monitor and evaluate the IFN neutralizing factors.

Journal of Oncology Pharmacy Practice, Vol. 2, No. 1, 22-28 (1996)
DOI: 10.1177/107815529600200103
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement